APOB and metabolic dysfunction-associated steatohepatitis: Specifically, mean (± SD) LDL-apoB FRR at baseline and week 12 of ACCi therapy were 38.5 ± 22.6%/day and 40.5 ± 14.6%/day among noncirrhotic subjects (P = 0.8197, N = 8, Fig. 2E), representing mean half-lives of 1.8 and 1.7 days as compared with 23.5 ± 15.4 and 51.38 ± 28.6%/day, representing mean half-lives of 2.9 and 1.4 days, respectively, in cirrhotic NASH subjects (P = 0.006, N = 8, Fig. 2F).